The firm scrapped its £450m investment despite the government's offer of support, the government says.

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

AstraZeneca has reinforced its commitment to advancing cancer care through early detection, innovative treatments, and equitable healthcare access in recognition of World Cancer Day 2025 under the ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in ...

AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in ...

AstraZeneca PLC closed 15.78% below its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca has scrapped plans to invest £ ... that talks over the plans between the new Labour government and the company had run into delays. Hunt called AstraZenca's announcement an "absolute ...

AstraZeneca has reaffirmed its commitment to transforming cancer care in Africa, unveiling new initiatives aimed at enhancing early detection, treatment, and patient support as part of World Cancer ...